Cargando…
A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab
OBJECTIVE: Mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, is effective for treating eosinophilic severe asthma. However, there is a need for more biomarkers that can predict the patient response to mepolizumab before starting therapy. This study aimed to identify a new biomarker in...
Autores principales: | Suzukawa, Maho, Ohshima, Nobuharu, Tashimo, Hiroyuki, Asari, Isao, Kobayashi, Nobuyuki, Shoji, Shunsuke, Tohma, Shigeto, Ohta, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725639/ https://www.ncbi.nlm.nih.gov/pubmed/32713920 http://dx.doi.org/10.2169/internalmedicine.5159-20 |
Ejemplares similares
-
Serum MMP3 and IL1-RA levels may be useful biomarkers for detecting asthma and chronic obstructive pulmonary disease overlap in patients with asthma
por: Takada, Kazufumi, et al.
Publicado: (2023) -
Severe Asthma Where Eosinophilic Granulomatosis with Polyangiitis Became Apparent after the Discontinuation of Dupilumab
por: Ikeda, Miki, et al.
Publicado: (2021) -
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment
por: Vantaggiato, Lorenza, et al.
Publicado: (2022) -
May mepolizumab used in asthma correct subfertility?
por: Ozden, Guzin, et al.
Publicado: (2021) -
The herpesvirus 8 encoded chemokines vCCL2 (vMIP-II) and vCCL3 (vMIP-III) target the human but not the murine lymphotactin receptor
por: Lüttichau, Hans R
Publicado: (2008)